Phase 2 N=245 Prevention of Post Sexual Assault Stress
Drug Use · Drug Abuse · Posttraumatic Stress Disorder
Primary: Drug Abuse Screening Test (DAST-10) — 1.97; 2.03; 1.18 units on a scale — p=.24
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Mixed Mullerian Tumors of the Uterus
Primary: Chemotherapy Completion Rate — 100 percentage of participants
Phase 2 N=25 This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Number of Patients With Drug-related Adverse Events — 12; 13 participants
Phase 2 N=619 Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Primary Hypercholesterolemia · Mixed Hyperlipidemia
Primary: Change From Baseline in Direct LDL-C at Week 8 — -2.0; -1.5; -4.2; 0.2 Percent change — p=0.06
Phase 2 N=222 Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis
Seasonal Allergic Rhinitis
Primary: Change in Total Nasal Symptom Score From Baseline to Day 14. — -2.70; -4.05; -4.72; -4.05 units on a scale
Phase 2 N=138 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
Advanced or Metastatic Melanoma
Primary: Percentage of Participants With Treatment-Related Grade 3-5 Adverse Events (AEs) During the Induction Period (Period 1 and 2) — 64.7; 51.4 Percentage of participants
Phase 2 N=27 Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Breast Cancer
Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…
Phase 2 N=44 Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years
Phase 2 N=153 D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 — 74.8; 74.0 percentage of participants — p=0.64
Phase 2 N=21 SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
Hepatitis B, Chronic
Primary: Percentage of Participants With Stable Virological Response — 100; 100.0; 52.9; 66.7 Percentage of Participants
Phase 2 N=77 Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
Gastroduodenal Ulcerations · Erosion
Primary: Degree of GI Injury at Day 15 — 23; 20; 11; 13 participants
Phase 2 N=72 A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
Psoriasis · Plaque Psoriasis
Primary: Overall Disease Severity Score (Success) — 30.6; 0.0 percentage of participants — p=<0.001
Phase 2 N=23 Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Number of Participants With Adverse Events — 23 participants
Phase 2 N=65 A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Mean Number of New Inflammatory MRI Lesions Per Monthly Scans — 0.4; 1.7 New Lesions — p=0.87
Phase 2 N=12 Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
Leber Congenital Amaurosis
Primary: Number of Participants Experiencing Ocular or Non-ocular Adverse Events — 6; 6 participants